Lexaria Bioscience Corp. (NASDAQ: LEXX) Making Great Strides Toward Filing IND Application for Patented DehydraTECH(TM) Technology

• Lexaria has begun the formal process of preparing an application for Investigational New Drug status for DehydraTECH(TM) and cannabidiol for hypertension
• The filing is being done with the assistance of an outside consultancy group, with Lexaria Bioscience designing non-clinical, clinical, and related product development required prior to the filing – all of which support Lexaria’s more ambitious goals
• There have been two successful human hypertension trials done with the combination DehydraTECH-CBD therapy in 2021, following an original human clinical study in 2018, and many animal studies
• Lexaria is making a strong case to support the efficacy of the technology for treating hypertension

Lexaria Bioscience (NASDAQ: LEXX), a global innovator currently enhancing the speed and efficiency of orally-delivered fat-soluble active molecules and drugs, is announcing that it has begun the formal process of preparing for Investigational New Drug (“IND”) certification with the US Food and Drug Administration (“FDA”). The IND will be for the company’s patented DehydraTECH-processed cannabidiol (“CBD”) as a prospective registered pharmaceutical treatment for high blood pressure (hypertension) (https://cnw.fm/gv5bN). With the help of an expert regulatory affairs and quality assurance consultancy group, Lexaria has begun preparations for a pre-IND meeting with the FDA and designing the non-clinical, clinical, and related product development IND-enabling work that must be completed prior to… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge. To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CBDWire.com Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer Do you have questions or are you interested in working with CNW? Ask Our Editor CBDWire (CBDW) Denver, Colorado www.CBDWire.com 303.498.7722 Office Editor@CBDWire.com CBDWire is part of the InvestorBrandNetwork.